Design Therapeutics, Inc. (DSGN) News

Design Therapeutics, Inc. (DSGN): $3.69

0.10 (-2.64%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add DSGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#124 of 362

in industry

Filter DSGN News Items

DSGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

DSGN News Highlights

  • For DSGN, its 30 day story count is now at 2.
  • Over the past 23 days, the trend for DSGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest DSGN News From Around the Web

Below are the latest news stories about DESIGN THERAPEUTICS INC that investors may wish to consider to help them evaluate DSGN as an investment opportunity.

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 18, 2023

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | November 25, 2023

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

Pratik Shah Takes Helm as CEO, Company Eyes Long-Term Growth

Yahoo | November 15, 2023

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic

Yahoo | November 13, 2023

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | October 15, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday!

William White on InvestorPlace | August 15, 2023

Why Shares of Design Therapeutics Are Plummeting on Tuesday

Shares of Design Therapeutics (NASDAQ: DSGN) were down more than 69% as of 2:15 p.m. ET on Tuesday. It also announced phase 1 results for DT-216 to treat FA, a rare, inherited disease that causes progressive damage to the nervous system. The disease affects more than 5,000 people in the U.S. and has no approved therapies yet.

Yahoo | August 15, 2023

Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls

Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls

Yahoo | August 15, 2023

4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi

Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Urban Outfitters, Keysight Technologies, Design Therapeutics, and Avid Technology. Citi downgraded Urban Outfitters (NASDAQ:URBN) to Neutral from Buy with a price target of $40.00 (from $36.00), as reported in real time on InvestingPro. Citi expects the company to beat Q2 earnings estimates and provide strong guidance next Tuesday but believes the company's risk/reward now looks balanced.

Yahoo | August 15, 2023

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and Report Data in the First Half of 2025 IND Submission for FECD GeneTAC™ Program On-track for the Second Half of 2023 $303.1 Million in Cash and Securities Expected to Support Operating Runway through 2026 CARLS

Yahoo | August 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!